Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immuno-oncology
Pharma
AZ, GSK make case for broad I-O uses in endometrial cancer
For AstraZeneca's and GSK's PD-(L)1/PARP regimens, the contribution of a PARP drug in a subset of endometrial cancer patients have come into question.
Angus Liu
Mar 18, 2024 11:05am
BeiGene finally snags FDA approval for PD-1 drug Tevimbra
Mar 15, 2024 8:39am
BMS shows I-O duo's power in first-line colorectal cancer
Jan 20, 2024 10:00am
Lynparza fails to improve on Keytruda in first-line lung cancer
Dec 7, 2023 9:21am
BMS buys Mirati for up to $5.8B as I-O giant branches out
Oct 9, 2023 3:29am
Novartis returns PD-1 to BeiGene in another cancer drug divorce
Sep 19, 2023 9:10am